The use of transgenic plants to express orally immunogenic protein antigens is an emerging strategy for vaccine biomanufacturing and delivery. This concept has particular suitability for developing countries. One factor that has limited the development of this technology is the relatively modest levels of accumulation of some antigenic proteins in plant tissues. We used fusion protein design to improve expression of the hepatitis B surface antigen (HBsAg) by attempting to mimic the process of HBsAg targeting to the endoplasmic reticulum of human liver cells during hepatitis B virus infection. We created a gene encoding a recombinant HBsAg modified to contain a plant signal peptide fused to its amino terminus. The signal peptide from soybean vegetative storage protein vspA (VSP␣S) directed endoplasmic reticulum targeting of HBsAg in plant cells, but was not cleaved and resulted in enhanced VSP␣S-HBsAg fusion accumulation. This product was more stable and presented the protective ''a'' antigenic determinant to significantly higher levels than unmodified native HBsAg expressed in plant cells. It also showed a greater extent of intermolecular disulfide bond formation and formation of virus-like particles. Moreover, VSP␣S-HBsAg stimulated higher levels of serum IgG than native HBsAg when injected into mice. We conclude that HBsAg tolerates a polypeptide fusion at the amino terminus and that VSP␣S-HBsAg is an improved antigen for plant-based expression of a subunit vaccine for hepatitis B virus.transgenic plants ͉ tobacco NT-1 cell ͉ vaccine H epatitis B virus (HBV) infection is an important global health problem, and vaccination is a proven strategy to control HBV infection. Current vaccines use yeast-derived recombinant hepatitis B surface antigen (rHBsAg) delivered by intramuscular injection, requiring trained medical practitioners and refrigerated storage, and are thus expensive to use. We have evaluated a new strategy for biomanufacturing the antigen to create a plant-derived oral vaccine, which could provide lower capital costs of production, mucosal immunization, and needlefree delivery of the final product. These advantages are particularly important for immunization programs in developing countries. Plant-derived HBsAg assembles into virus-like particles (VLPs) (1, 2) as in human (3), Chinese hamster ovary (4), and yeast (5) cells. Potato-derived HBsAg is orally immunogenic in mice, but high doses are needed (2, 6), creating a need for enhanced accumulation of the antigen in plant tissues if acceptable amounts of the plant material are to be delivered orally.HBsAg is a transmembrane protein with uncleaved internal signal sequences that facilitate cotranslational translocation and integration of HBsAg into the endoplasmic reticulum (ER) membrane (7). Subsequently, HBsAg dimers are rapidly formed via intermolecular disulfide bonds, catalyzed by protein disulfide isomerase (PDI). The protein-membrane complexes then assemble and extrude into the ER lumen (8) and are transported to the post-ER-pre-Golgi intermedia...